Articles

Subgroup Analysis from REVEL: Safety by Histology and Efficacy in Nonsquamous NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from KEYNOTE-021 Cohort D: a Phase 1 Study of Pembrolizumab plus Ipilimumab as Second-line Therapy for Advanced NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Clinical Correlation and Frequency of PD-L1 Expression in EGFR-Mutant and ALK-Rearranged NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from POPLAR: Efficacy, Safety, and Predictive Biomarker Results From a Randomized Phase 2 Study Comparing MPDL3280A vs Docetaxel in NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Checkmate 017: A Phase 3 Study of Nivolumab vs Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Final Overall Survival Results of the Phase 3 PROCLAIM Trial

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Necitumumab in Metastatic Squamous NSCLC: Establishing a Value-Based Cost

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Phase 1-1B Trial of Tivantinib in Combination with Carboplatin and Pemetrexed as First-Line Treatment in Patients with Advanced Nonsquamous NSCLC or Malignant Pleural Mesothelioma

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Page 195 of 330